Next Article in Journal
Ciliopathy-Associated Protein Kinase ICK Requires Its Non-Catalytic Carboxyl-Terminal Domain for Regulation of Ciliogenesis
Next Article in Special Issue
The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models
Previous Article in Journal
GEDS: A Gene Expression Display Server for mRNAs, miRNAs and Proteins
Previous Article in Special Issue
Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
Review

Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer

1
INSERM Unit 1151, Faculté de Médecine, Université Paris Descartes, 75014 Paris, France
2
Laboratoire de Biochimie A, Hôpital Necker-Enfants Malades, 75015 Paris, France
*
Author to whom correspondence should be addressed.
Cells 2019, 8(7), 676; https://doi.org/10.3390/cells8070676
Received: 3 June 2019 / Revised: 30 June 2019 / Accepted: 1 July 2019 / Published: 3 July 2019
The main issue concerning localized prostate cancers is the lack of a suitable marker which could help patients’ stratification at diagnosis and distinguish those with a benign disease from patients with a more aggressive cancer. Circulating Tumor Cells (CTC) are spread in the blood by invasive tumors and could be the ideal marker in this setting. Therefore, we have compiled data from the literature in order to obtain clues about the clinical impact of CTC in patients with localized prostate cancer. Forty-three publications have been found reporting analyses of CTC in patients with non-metastatic prostate cancer. Of these, we have made a further selection of 11 studies targeting patients with clinical or pathological stages T1 and T2 and reporting the clinical impact of CTC. The results of this search show encouraging data toward the use of CTC in patients with early-stage cancer. However, they also highlight the lack of standardized methods providing a highly sensitive and specific approach for the detection of prostate-derived CTC. View Full-Text
Keywords: prostate cancer (PCa); circulating tumor cells (CTC); liquid biopsy prostate cancer (PCa); circulating tumor cells (CTC); liquid biopsy
MDPI and ACS Style

Broncy, L.; Paterlini-Bréchot, P. Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer. Cells 2019, 8, 676. https://doi.org/10.3390/cells8070676

AMA Style

Broncy L, Paterlini-Bréchot P. Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer. Cells. 2019; 8(7):676. https://doi.org/10.3390/cells8070676

Chicago/Turabian Style

Broncy, Lucile, and Patrizia Paterlini-Bréchot. 2019. "Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer" Cells 8, no. 7: 676. https://doi.org/10.3390/cells8070676

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop